title: Who could benefit most from treatment of acute pulmonary embolism with rivaroxaban? Commentary to the article: "Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy….
authors.affiliation: Institute of Cardiology, Jagiellonian University Medical College and Centre for Research and Medical Technology, John Paul II Hospital, Krakow, Poland. anettaundas@yahoo.com.
authors.forename: Anetta
authors.initials: A
authors.lastname: Undas
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D065427:Factor Xa Inhibitors / Q000008:administration & dosage; D006760:Hospitalization; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D011655:Pulmonary Embolism / Q000188:drug therapy; D000069552:Rivaroxaban; D013876:Thiophenes / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban